Neuronetics, Inc. (STIM): Price and Financial Metrics
GET POWR RATINGS... FREE!
STIM POWR Grades
- Value is the dimension where STIM ranks best; there it ranks ahead of 68.49% of US stocks.
- The strongest trend for STIM is in Stability, which has been heading up over the past 179 days.
- STIM ranks lowest in Growth; there it ranks in the 12th percentile.
STIM Stock Summary
- STIM's went public 3.76 years ago, making it older than merely 12.78% of listed US stocks we're tracking.
- The volatility of Neuronetics Inc's share price is greater than that of 98.46% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for STIM comes in at -102.2% -- higher than that of only 3.78% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Neuronetics Inc, a group of peers worth examining would be EKSO, NVRO, APYX, IGC, and CLS.
- STIM's SEC filings can be seen here. And to visit Neuronetics Inc's official web site, go to www.neurostar.com.
STIM Valuation Summary
- In comparison to the median Healthcare stock, STIM's EV/EBIT ratio is 118.43% lower, now standing at -5.4.
- STIM's price/earnings ratio has moved up 20.2 over the prior 39 months.
- Over the past 39 months, STIM's price/sales ratio has gone down 8.
Below are key valuation metrics over time for STIM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| STIM | 2021-08-31 | 3.2 | 1.8 | -7.9 | -5.4 |
| STIM | 2021-08-30 | 3.2 | 1.8 | -7.6 | -5.1 |
| STIM | 2021-08-27 | 3.2 | 1.8 | -7.9 | -5.4 |
| STIM | 2021-08-26 | 3.4 | 1.9 | -8.2 | -5.8 |
| STIM | 2021-08-25 | 3.6 | 2.0 | -8.8 | -6.5 |
| STIM | 2021-08-24 | 3.7 | 2.1 | -9.0 | -6.7 |
STIM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- STIM has a Quality Grade of D, ranking ahead of 12.85% of graded US stocks.
- STIM's asset turnover comes in at 0.477 -- ranking 99th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows STIM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.477 | 0.791 | -0.385 |
| 2021-03-31 | 0.514 | 0.781 | -0.493 |
| 2020-12-31 | 0.605 | 0.765 | -0.637 |
| 2020-09-30 | 0.588 | 0.765 | -0.893 |
| 2020-06-30 | 0.584 | 0.752 | -0.892 |
| 2020-03-31 | 0.609 | 0.749 | -0.766 |
STIM Price Target
For more insight on analysts targets of STIM, see our STIM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.50 | Average Broker Recommendation | 1.2 (Strong Buy) |
STIM Stock Price Chart Interactive Chart >
STIM Price/Volume Stats
| Current price | $3.21 | 52-week high | $16.25 |
| Prev. close | $3.44 | 52-week low | $1.98 |
| Day low | $3.13 | Volume | 189,606 |
| Day high | $3.39 | Avg. volume | 251,144 |
| 50-day MA | $2.87 | Dividend yield | N/A |
| 200-day MA | $3.90 | Market Cap | 85.48M |
Neuronetics, Inc. (STIM) Company Bio
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company’s NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was founded in 2003 and is based in Malvern, Pennsylvania.
Latest STIM News From Around the Web
Below are the latest news stories about Neuronetics Inc that investors may wish to consider to help them evaluate STIM as an investment opportunity.
Neuronetics to Report Fourth Quarter and Fiscal Year 2021 Financial and Operating Results and Host Conference CallMALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release fourth quarter and fiscal year 2021 financial and operating results prior to market open on Tuesday, March 8, 2022. The Company will host a conference call to review its results at 8:30 a.m |
Neuronetics Announces Amendment of Credit Facility with SLR Investment Corp.MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced it has amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment Corp. (SLR), which was originally entered into on March 2, 2020 and subsequently amended on April 20, |
After Plunging 24.2% in 4 Weeks, Here's Why the Trend Might Reverse for Neuronetics (STIM)Neuronetics (STIM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Neurostimulation Devices Market revenue to cross USD 13.6 Bn by 2027: Global Market Insights Inc.Major neurostimulation devices market players include Abbott, Boston Scientific, IntraPace, Laborie, LivaNova, Medtronic, Neuronetics, SPR Therapeutics, Cyberonics, ElectroCore Inc., Aleva Neurotherapeutics SA, Synapse Biomedical Inc., MicroTransponder, RS Medical, Helbling holding Ag, EndoStim Inc., and BioControl Medical. SELBYVILLE, Del. , Jan. 20, 2022 /PRNewswire/ -- The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the most recent study by Global Market Insights Inc. Increasing adoption and introduction of advanced neurostimulation devices will drive the overall market growth. Increasing demand for minimally invasive surgeries in developed countries attributed to the rising preference among patients for shorter ... |
Stay Away From Southeast Asian Loyalty Play Society PassSociety Pass CEO Dennis Nguyen has big dreams but his company did less than $100k in sales during the quarter before SOPA stock went public. |
STIM Price Returns
| 1-mo | 19.78% |
| 3-mo | 2.88% |
| 6-mo | -28.03% |
| 1-year | -79.96% |
| 3-year | -74.34% |
| 5-year | N/A |
| YTD | -28.03% |
| 2021 | -59.86% |
| 2020 | 147.44% |
| 2019 | -76.80% |
| 2018 | N/A |
| 2017 | N/A |
Continue Researching STIM
Here are a few links from around the web to help you further your research on Neuronetics Inc's stock as an investment opportunity:Neuronetics Inc (STIM) Stock Price | Nasdaq
Neuronetics Inc (STIM) Stock Quote, History and News - Yahoo Finance
Neuronetics Inc (STIM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...